FDA Clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track
COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) (“FluoGuide” or the “Company”), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces that the U.S. Food and …